Steven Francis Powell MD
Head & Neck Cancer, Hematologic Oncology, Melanoma, Thoracic Cancer
Medical Fellow
Join to View Full Profile
1309 W 17th St Ste 10114-100 Phillips-Wangensteen Building, Mmc 284Sioux Falls, SD 57104
Phone+1 612-626-5031
Dr. Powell is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of MinnesotaFellowship, Hematology and Medical Oncology, 2010 - 2013- University of MinnesotaResidency, Internal Medicine, 2006 - 2009
University of South Dakota, Sanford School of MedicineClass of 2006
Certifications & Licensure
SD State Medical License Active through 2027
MN State Medical License 2008 - 2025
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors Start of enrollment: 2017 Apr 17
- 9-ING-41 in Patients with Advanced Cancers Start of enrollment: 2019 Jan 04
Roles: Contact
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer Start of enrollment: 2016 Mar 14
Roles: Contact, Principal Investigator
- Join now to see all
Publications & Presentations
PubMed
- 6 citationsRadiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label,...Loren K Mell, Pedro A Torres-Saavedra, Stuart J Wong, Julie A Kish, Steven S Chang
The Lancet. Oncology. 2024-12-01 - Palbociclib in Patients With Head and Neck Cancer and Other Tumors WithAlterations: Results From the Targeted Agent and Profiling Utilization Registry Study.Francis P Worden, Evan Pisick, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer
JCO Precision Oncology. 2024-10-01 - Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies.Benedito A Carneiro, Ludimila Cavalcante, Devalingam Mahalingam, Anwaar Saeed, Howard Safran
Clinical Cancer Research. 2024-02-01
Press Mentions
Cancer Patients in Ireland Benefit from Sanford ExpertiseJuly 12th, 2021
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
